Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence

Neurourology and Urodynamics

Volumn 25, Issue 3, 2006, Pages 228-235

  Homma, Yukio ^a   Koyama, Nobuyuki ^b  

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Health related quality of life; Kings Health Questionnaire; Minimal clinically important change; Overactive bladder; Urinary incontinence

Indexed keywords

OXYBUTYNIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; EMOTION; FEMALE; HEALTH STATUS; HUMAN; JAPAN; KINGS HEALTH QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERACTIVE BLADDER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SLEEP; SOCIAL INTERACTION; TREATMENT OUTCOME; URGE INCONTINENCE; URINE INCONTINENCE;

ADMINISTRATION, CUTANEOUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; SYNDROME; URINARY INCONTINENCE;

EID: 33646535617     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20195     Document Type: Article

References (17)

1. Abrams P, Wein AJ. 2000. Introduction: Overactive bladder and its treatments. Urology 55:1-2.
2. Abrams P, Cardozo L, Fall M, et al. 2002. The standardization of terminology of lower urinary tract function: Report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodynam 21:167-78.
3. Andersson KE. 2000. Treatment of overactive bladder: Other drug mechanisms. Urology 55:51-7.
4. Barber BL, Santanello NC, Epstein RS. 1996. Impact of the global on patient perceivable change in an asthma specific QOL questionnaire. Qual Life Res 5:117-22.
5. Hays RD, Woolley JM. 2000. The concept of clinically meaningful difference in health-related quality-of-life research. Pharmacoeconomics 18:419-23.
6. Homma Y, Gotoh M, Ando T, et al. 1999. Development of Japanese version of QOL questionnaires for urinary incontinence. Neurogenic Bladder Society 10:225-36 (in Japanese).
7. Homma Y, Kakizaki H, Gotoh M, et al. 2003. Epidemiologic survey on lower urinary tract symptoms in Japan. Neurogenic Bladder Society 14:266-77 (in Japanese).
8. Jaeschke R, Singer J, Guyatt GH. 1989. Measurement of health status: Ascertaining the minimal clinically important difference. Contrl Clin Trials 10:407-15.
9. Kelleher CJ, Cardozo LD, Khullar V, et al. 1997. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104:1374-79.
10. Kelleher CJ, Resse PR, Pleil AM, et al. 2002. Health-related quality of life of patients receiving extended-release toherodine for overactive bladder. Am J Manag Care 8:608-15.
11. Mcleod LD, Fehnel SE, Brandman J, et al. 2003. Evaluating minimal clinically important differences for the Acne-specific quality of life questionnaire. Pharmacoeconomics 21:1069-79.
12. Milsom I, Abrams P, Cardozo L, et al. 2001. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760-6.
13. Samsa G, Edelman D, Rothman ML, et al. 1999. Determining clinically important differences in health status measures. A general approach with illustration to the health utilities index mark II. Pharmacoeconomics 15:141-55.
14. Stewart WF, Van Rooyen JB, Cundiff GW, et al. 2003. Prevalence and burden of overactive bladder in the United States. W J Urology 20:327-36.
15. Uemura S, Homma Y. 2004. Reliability and validity of King's health questionnaire in patients with symptom of overactive bladder with urge incontinence in Japan. Neurourol Urodynam 23:94-100.
16. Wein AJ, Rovner ES. 2002. Definition and epidemiology of overactive bladder. Urology 60:7-12.
17. Yoshimura N, Chancellor MB. 2002. Current and future pharmacological treatment for overactive bladder. J Urology 168:1897-913.